                         SEQUENCE LISTING

<110>  Institut National de la Sant et de la Recherche Mdicale 
       (INSERM)
 
<120>  Chimeric peptides including a penetrating peptide and a binding 
       domain of PP2A catalytic subunit to caspase-9

<130>  BET 11P2313

<160>  72    

<170>  PatentIn version 3.5

<210>  1
<211>  31
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  DPT-PP2A peptides


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa is vacant, K or VK

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Xaa is vacant, K or KI

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  Xaa is vacant, or an amino acid sequence of 1 to 4 amino acids

<400>  1

Xaa Lys Lys Lys Ile Lys Arg Glu Ile Xaa Xaa Asp Thr Leu Asp His 
1               5                   10                  15      


Ile Arg Ala Leu Asp Arg Leu Gln Glu Val Pro His Glu Gly Pro 
            20                  25                  30      


<210>  2
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  DPT sequence


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa is vacant or K or VK

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Xaa is vacant or K or KI

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  Xaa is vacant or an amino acid sequence of 1 to 4 amino acids

<400>  2

Xaa Lys Lys Lys Ile Lys Arg Glu Ile Xaa Xaa 
1               5                   10      


<210>  3
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  human PP2A domain interacting with C9

<400>  3

Asp Thr Leu Asp His Ile Arg Ala Leu Asp Arg Leu Gln Glu Val Pro 
1               5                   10                  15      


His Glu Gly Pro 
            20  


<210>  4
<211>  30
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  DPT sequence fused to PP2Ah


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa is vacant, K or VK

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Xaa is vacant, K or KI

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  Xaa is vacant, or an amino acid sequence of 1 to amino acids

<400>  4

Xaa Lys Lys Lys Ile Lys Arg Glu Ile Xaa Asp Thr Leu Asp His Ile 
1               5                   10                  15      


Arg Ala Leu Asp Arg Leu Gln Glu Val Pro His Glu Gly Pro 
            20                  25                  30  


<210>  5
<211>  32
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  DPT-PP2Ah

<400>  5

Val Lys Lys Lys Lys Ile Lys Arg Glu Ile Lys Ile Asp Thr Leu Asp 
1               5                   10                  15      


His Ile Arg Ala Leu Asp Arg Leu Gln Glu Val Pro His Glu Gly Pro 
            20                  25                  30          


<210>  6
<211>  27
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  DPT-C9 peptides


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa is vacant, K or VK

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Xaa is vacant, K or KI

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  Xaa is vacant, or an amino acid sequence of 1 to 4 amin acids

<220>
<221>  MISC_FEATURE
<222>  (13)..(13)
<223>  Xaa is V or I

<220>
<221>  MISC_FEATURE
<222>  (20)..(20)
<223>  Xaa is F or L

<220>
<221>  MISC_FEATURE
<222>  (25)..(25)
<223>  Xaa is R or H

<220>
<221>  MISC_FEATURE
<222>  (27)..(27)
<223>  Xaa is vacant, or E, ED, or EDL

<400>  6

Xaa Lys Lys Lys Ile Lys Arg Glu Ile Xaa Xaa Tyr Xaa Glu Thr Leu 
1               5                   10                  15      


Asp Gly Ile Xaa Glu Gln Trp Ala Xaa Ser Xaa 
            20                  25          


<210>  7
<211>  30
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  human DPT-C9

<400>  7

Val Lys Lys Lys Lys Ile Lys Arg Glu Ile Lys Ile Tyr Val Glu Thr 
1               5                   10                  15      


Leu Asp Gly Ile Phe Glu Gln Trp Ala His Ser Glu Asp Leu 
            20                  25                  30  


<210>  8
<211>  30
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mouse DPT-C9

<400>  8

Val Lys Lys Lys Lys Ile Lys Arg Glu Ile Lys Ile Tyr Ile Glu Thr 
1               5                   10                  15      


Leu Asp Gly Ile Leu Glu Gln Trp Ala Arg Ser Glu Asp Leu 
            20                  25                  30  


<210>  9
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  DPT sequence

<400>  9

Val Lys Lys Lys Lys Ile Lys Arg Glu Ile Lys 
1               5                   10      


<210>  10
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mouse C9 domain interacting with PP2A

<400>  10

Tyr Ile Glu Thr Leu Asp Gly Ile Leu Glu Gln Trp Ala Arg Ser Glu 
1               5                   10                  15      


Asp Leu 
        


<210>  11
<211>  30
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  DPT-C9r

<400>  11

Val Lys Lys Lys Lys Ile Lys Arg Glu Ile Lys Ile Leu Asp Glu Ser 
1               5                   10                  15      


Arg Ala Trp Gln Glu Leu Ile Gly Asp Leu Thr Glu Ile Tyr 
            20                  25                  30  


<210>  12
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tat penetrating peptide

<400>  12

Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg 
1               5                   10      


<210>  13
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PP2A peptide

<400>  13

Asp Thr Leu Asp His Ile Arg Ala Leu Asp Arg Leu 
1               5                   10          


<210>  14
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PP2A peptide

<400>  14

Leu Asp His Ile Arg Ala Leu Asp Arg Leu Gln Glu 
1               5                   10          


<210>  15
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PP2A peptide

<400>  15

His Ile Arg Ala Leu Asp Arg Leu Gln Glu Val Pro 
1               5                   10          


<210>  16
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PP2A peptide

<400>  16

Arg Ala Leu Asp Arg Leu Gln Glu Val Pro His Glu 
1               5                   10          


<210>  17
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PP2A peptide

<400>  17

Leu Asp Arg Leu Gln Glu Val Pro His Glu Gly Pro 
1               5                   10          


<210>  18
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide C9h sequence

<400>  18

Tyr Val Glu Thr Leu Asp Gly Ile Phe Glu Gln Trp Ala His Ser Glu 
1               5                   10                  15      


Asp Leu 
        


<210>  19
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PP2Ac peptide

<400>  19

Thr Leu Asp His Ile Arg Ala Leu Asp Arg Leu Gln Glu Val Pro His 
1               5                   10                  15      


Glu Gly Pro 
            


<210>  20
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PP2Ac peptide

<400>  20

Leu Asp His Ile Arg Ala Leu Asp Arg Leu Gln Glu Val Pro His Glu 
1               5                   10                  15      


Gly Pro 
        


<210>  21
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PP2Ac peptide

<400>  21

Asp His Ile Arg Ala Leu Asp Arg Leu Gln Glu Val Pro His Glu Gly 
1               5                   10                  15      


Pro 
    


<210>  22
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PP2Ac peptide

<400>  22

His Ile Arg Ala Leu Asp Arg Leu Gln Glu Val Pro His Glu Gly Pro 
1               5                   10                  15      


<210>  23
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PP2Ac peptide

<400>  23

Asp Thr Leu Asp His Ile Arg Ala Leu Asp Arg Leu Gln Glu Val Pro 
1               5                   10                  15      


His Glu Gly 
            


<210>  24
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PP2Ac peptide

<400>  24

Asp Thr Leu Asp His Ile Arg Ala Leu Asp Arg Leu Gln Glu Val Pro 
1               5                   10                  15      


His Glu 
        


<210>  25
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PP2Ac peptide

<400>  25

Asp Thr Leu Asp His Ile Arg Ala Leu Asp Arg Leu Gln Glu Val Pro 
1               5                   10                  15      


His 
    


<210>  26
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PP2Ac peptide

<400>  26

Asp Thr Leu Asp His Ile Arg Ala Leu Asp Arg Leu Gln Glu Val Pro 
1               5                   10                  15      


<210>  27
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PP2Ac peptide

<400>  27

Thr Leu Asp His Ile Arg Ala Leu Asp Arg Leu Gln Glu Val Pro His 
1               5                   10                  15      


Glu Gly 
        


<210>  28
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PP2Ac peptide

<400>  28

Leu Asp His Ile Arg Ala Leu Asp Arg Leu Gln Glu Val Pro His Glu 
1               5                   10                  15      


<210>  29
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PP2Ac peptide

<400>  29

Thr Leu Asp His Ile Arg Ala Leu Asp Arg Leu Gln Glu Val Pro His 
1               5                   10                  15      


Glu 
    


<210>  30
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PP2Ac peptide

<400>  30

Leu Asp His Ile Arg Ala Leu Asp Arg Leu Gln Glu Val Pro His Glu 
1               5                   10                  15      


Gly 
    


<210>  31
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CPP sequence 1

<400>  31

Arg Gln Lys Arg Leu Ile Arg Gln Lys Arg Leu Ile Arg Gln Lys Arg 
1               5                   10                  15      


Leu Ile 
        


<210>  32
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CPP sequence 2

<400>  32

Arg His Ser Arg Ile Gly Arg His Ser Arg Ile Gly Arg His Ser Arg 
1               5                   10                  15      


Ile Gly 
        


<210>  33
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CPP sequence 3

<400>  33

Arg His Ser Arg Ile Gly Ile Ile Gln Gln Arg Arg Thr Arg Asn Gly 
1               5                   10                  15      


<210>  34
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CPP sequence 4

<400>  34

Arg His Ser Arg Ile Gly Val Thr Arg Gln Arg Arg Ala Arg Asn Gly 
1               5                   10                  15      


<210>  35
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CPP sequence 5

<400>  35

Arg Arg Arg Arg Arg Arg Arg Ser Arg Gly Arg Arg Arg Thr Tyr 
1               5                   10                  15  


<210>  36
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CPP sequence 6


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa is vacant or K or VK

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Xaa is vacant or K or KI

<400>  36

Xaa Lys Lys Lys Ile Lys Arg Glu Ile Xaa 
1               5                   10  


<210>  37
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Tat peptide 2

<400>  37

Arg Lys Lys Arg Arg Gln Arg Arg Arg 
1               5                   


<210>  38
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Polyarginine peptide R9

<400>  38

Arg Arg Arg Arg Arg Arg Arg Arg Arg 
1               5                   


<210>  39
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Polyarginine peptide R11

<400>  39

Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg 
1               5                   10      


<210>  40
<211>  32
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HA2-R9 peptide

<400>  40

Gly Leu Phe Glu Ala Ile Glu Gly Phe Ile Glu Asn Gly Trp Glu Gly 
1               5                   10                  15      


Met Ile Asp Gly Trp Tyr Gly Arg Arg Arg Arg Arg Arg Arg Arg Arg 
            20                  25                  30          


<210>  41
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Penetratin peptide

<400>  41

Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys 
1               5                   10                  15      


<210>  42
<211>  27
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Transportan peptide

<400>  42

Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly Lys Ile Asn Leu 
1               5                   10                  15      


Lys Ala Leu Ala Ala Leu Ala Lys Lys Ile Leu 
            20                  25          


<210>  43
<211>  33
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Maurocalcine peptide

<400>  43

Gly Asp Cys Leu Pro His Leu Lys Leu Cys Lys Glu Asn Lys Asp Cys 
1               5                   10                  15      


Cys Ser Lys Lys Cys Lys Arg Arg Gly Thr Asn Ile Glu Lys Arg Cys 
            20                  25                  30          


Arg 
    


<210>  44
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Decalysine peptide

<400>  44

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys 
1               5                   10  


<210>  45
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  HIV-Tat derived PTD4 peptide

<400>  45

Tyr Ala Arg Ala Ala Ala Arg Gln Ala Arg Ala 
1               5                   10      


<210>  46
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Hepatitis B virus Translocation Motif (PTM) peptide

<400>  46

Pro Leu Ser Ser Ile Phe Ser Arg Ile Gly Asp Pro 
1               5                   10          


<210>  47
<211>  28
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mPrP1-28 peptide

<400>  47

Met Ala Asn Leu Gly Tyr Trp Leu Leu Ala Leu Phe Val Thr Met Trp 
1               5                   10                  15      


Thr Asp Val Gly Leu Cys Lys Lys Arg Pro Lys Pro 
            20                  25              


<210>  48
<211>  35
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  POD peptide

<400>  48

Gly Gly Gly Ala Arg Lys Lys Ala Ala Lys Ala Ala Arg Lys Lys Ala 
1               5                   10                  15      


Ala Lys Ala Ala Arg Lys Lys Ala Ala Lys Ala Ala Arg Lys Lys Ala 
            20                  25                  30          


Ala Lys Ala 
        35  


<210>  49
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  pVEC peptide

<400>  49

Leu Leu Ile Ile Leu Arg Arg Arg Arg Ile Arg Lys Gln Ala His Ala 
1               5                   10                  15      


His Ser Lys 
            


<210>  50
<211>  23
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  EB1 peptide

<400>  50

Leu Ile Arg Leu Trp Ser His Leu Ile His Ile Trp Phe Gln Asn Arg 
1               5                   10                  15      


Arg Leu Lys Trp Lys Lys Lys 
            20              


<210>  51
<211>  22
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Rath peptide

<400>  51

Thr Pro Trp Trp Arg Leu Trp Thr Lys Trp His His Lys Arg Arg Asp 
1               5                   10                  15      


Leu Pro Arg Lys Pro Glu 
            20          


<210>  52
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CADY peptide

<400>  52

Gly Leu Trp Arg Ala Leu Trp Arg Leu Leu Arg Ser Leu Trp Arg Leu 
1               5                   10                  15      


Leu Trp Arg Ala 
            20  


<210>  53
<211>  24
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Histatin 5 peptide

<400>  53

Asp Ser His Ala Lys Arg His His Gly Tyr Lys Arg Lys Phe His Glu 
1               5                   10                  15      


Lys His His Ser His Arg Gly Tyr 
            20                  


<210>  54
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Antp peptide

<400>  54

Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys 
1               5                   10                  15      


<210>  55
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Cyt86-101 peptide

<400>  55

Lys Lys Lys Glu Glu Arg Ala Asp Leu Ile Ala Tyr Leu Lys Lys Ala 
1               5                   10                  15      


<210>  56
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PP2Ac chimeric peptide

<400>  56

Arg Gln Lys Arg Leu Ile Arg Gln Lys Arg Leu Ile Arg Gln Lys Arg 
1               5                   10                  15      


Leu Ile Asp Thr Leu Asp His Ile Arg Ala Leu Asp Arg Leu Gln Glu 
            20                  25                  30          


Val Pro His Glu Gly Pro 
        35              


<210>  57
<211>  38
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PP2Ac chimeric peptide

<400>  57

Arg His Ser Arg Ile Gly Arg His Ser Arg Ile Gly Arg His Ser Arg 
1               5                   10                  15      


Ile Gly Asp Thr Leu Asp His Ile Arg Ala Leu Asp Arg Leu Gln Glu 
            20                  25                  30          


Val Pro His Glu Gly Pro 
        35              


<210>  58
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PP2Ac chimeric peptide

<400>  58

Arg His Ser Arg Ile Gly Ile Ile Gln Gln Arg Arg Thr Arg Asn Gly 
1               5                   10                  15      


Asp Thr Leu Asp His Ile Arg Ala Leu Asp Arg Leu Gln Glu Val Pro 
            20                  25                  30          


His Glu Gly Pro 
        35      


<210>  59
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PP2Ac chimeric peptide

<400>  59

Arg His Ser Arg Ile Gly Val Thr Arg Gln Arg Arg Ala Arg Asn Gly 
1               5                   10                  15      


Asp Thr Leu Asp His Ile Arg Ala Leu Asp Arg Leu Gln Glu Val Pro 
            20                  25                  30          


His Glu Gly Pro 
        35      


<210>  60
<211>  35
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PP2Ac chimeric peptide

<400>  60

Arg Arg Arg Arg Arg Arg Arg Ser Arg Gly Arg Arg Arg Thr Tyr Asp 
1               5                   10                  15      


Thr Leu Asp His Ile Arg Ala Leu Asp Arg Leu Gln Glu Val Pro His 
            20                  25                  30          


Glu Gly Pro 
        35  


<210>  61
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  DPT-PP2A peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa is vacant, or K, or VK

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Xaa is vacant, or K, or KI

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  Xaa is vacant, or is an amino acid sequence if 1 to 4 amino acids

<400>  61

Xaa Lys Lys Lys Ile Lys Arg Glu Ile Xaa Xaa Leu Asp His Ile Arg 
1               5                   10                  15      


Ala Leu Asp Arg Leu Gln Glu Val Pro His Glu Gly Pro 
            20                  25                  


<210>  62
<211>  28
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  DPT-PP2A peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa is vacant, or K, or VK

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Xaa is vacant, or K, or KI

<400>  62

Xaa Lys Lys Lys Ile Lys Arg Glu Ile Xaa Leu Asp His Ile Arg Ala 
1               5                   10                  15      


Leu Asp Arg Leu Gln Glu Val Pro His Glu Gly Pro 
            20                  25              


<210>  63
<211>  30
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  DPT-PP2A peptide

<400>  63

Val Lys Lys Lys Lys Ile Lys Arg Glu Ile Lys Ile Leu Asp His Ile 
1               5                   10                  15      


Arg Ala Leu Asp Arg Leu Gln Glu Val Pro His Glu Gly Pro 
            20                  25                  30  


<210>  64
<211>  60
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  PP2Ac nucleotidic sequence

<400>  64
gatacactgg atcatatcag agcacttgat cgcctacaag aagttcccca tgagggtcca       60


<210>  65
<211>  96
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  DPT-PP2Ah nucleotidic sequence

<400>  65
gtaaagaaga agaaaatcaa gagagagatt aagattgata cactggatca tatcagagca       60

cttgatcgcc tacaagaagt tccccatgag ggtcca                                 96


<210>  66
<211>  114
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  PP2Ac chimeric peptide nucleotidic sequence

<400>  66
cgccagaaac gcctgattcg ccagaaacgc ctgattcgcc agaaacgcct gattgataca       60

ctggatcata tcagagcact tgatcgccta caagaagttc cccatgaggg tcca            114


<210>  67
<211>  114
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  PP2Ac chimeric peptide nucleotidic sequence

<400>  67
cgccatagcc gcattggccg ccatagccgc attggccgcc atagccgcat tggcgataca       60

ctggatcata tcagagcact tgatcgccta caagaagttc cccatgaggg tcca            114


<210>  68
<211>  108
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  PP2Ac chimeric peptide nucleotidic sequence

<400>  68
cgacatagca gaataggcat tattcaacag aggagaacaa gaaatggaga tacactggat       60

catatcagag cacttgatcg cctacaagaa gttccccatg agggtcca                   108


<210>  69
<211>  108
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  PP2Ac chimeric peptide nucleotidic sequence

<400>  69
cgccatagcc gcattggcgt gacccgccag cgccgcgcgc gcaacggcga tacactggat       60

catatcagag cacttgatcg cctacaagaa gttccccatg agggtcca                   108


<210>  70
<211>  105
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  PP2Ac chimeric peptide nucleotidic sequence

<400>  70
cgccgccgcc gccgccgccg cagccgcggc cgccgccgca cctatgatac actggatcat       60

atcagagcac ttgatcgcct acaagaagtt ccccatgagg gtcca                      105


<210>  71
<211>  90
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  PP2Ac chimeric peptide nucleotidic sequence

<400>  71
gtaaagaaga agaaaatcaa gagagagatt aagattctgg atcatatcag agcacttgat       60

cgcctacaag aagttcccca tgagggtcca                                        90


<210>  72
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  C9x peptide


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa is V or I

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  Xaa is F or L

<220>
<221>  MISC_FEATURE
<222>  (14)..(14)
<223>  Xaa is R or H

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa is vacant or E or ED or EDL

<400>  72

Tyr Xaa Glu Thr Leu Asp Gly Ile Xaa Glu Gln Trp Ala Xaa Ser Xaa 
1               5                   10                  15      


